Type 2 diabetes mellitus has emerged as an important condition of older pat
ients in which both microvascular and macrovascular complications are a com
mon cause of morbidity and mortality. In contrast to type 1 diabetes mellit
us, this endocrinopathy is clustered in minority populations and has both s
trong genetic and environmental factors that influence disease manifestatio
n. A number of physiological alterations of glucose metabolism including he
patic overproduction of glucose, and reduced glucose utilization by periphe
ral tissues as a result of insulin resistance contribute to the development
of the metabolic manifestations of this disease. Ultimately pancreatic fai
lure and reduced insulin secretion lead to hyperglycemia and the diabetic s
tate. Frequently, many of these metabolic manifestations, or what has been
termed Syndrome X, antecede the development of overt diabetes by many years
. This syndrome is manifest clinically by such cardiovascular risk factors
as hypertension, dyslipidemia, and coagulation abnormalities. This abnormal
metabolic milieu contributes to the high prevalence of macrovascular compl
ications including coronary artery disease as well as more generalized athe
rosclerosis. Microvascular complications have only more recently been recog
nized as an important and frequent complication of type 2 diabetes. Among t
he elderly and minority populations, this has become the single most import
ant cause of end-stage renal failure that necessitates renal replacement th
erapies. The outcome for these patients on hemodialysis, the modality most
frequently selected, is poor, with the majority of these patients dying of
cardiovascular causes. Unfortunately, interventional strategies to reduce o
r prevent the microvascular and macrovascular complications have only recen
tly received the needed attention and will require considerable effort and
resources to improve the clinical outcomes and life expectancies for these
patients. (C) 2000 by the National Kidney Foundation, Inc.